Roundtable Discussion: Preparing a National Biodefense: S. 975: Hearing Before the Subcommittee on Bioterrorism and Public Health Preparedness of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Ninth Congress, First Session on Examining S. 975, July 21, 2005 [open pdf - 90KB]
From the opening statement of Joseph I. Lieberman: "The BioShield law that was enacted last year takes the first step, but unfortunately, my conclusion is, without additional reforms, companies are not likely to risk their own capital to fund the necessary research, leaving us with a Government funding model that will be expensive, and I am afraid will not produce the results we need. The concepts in our legislation, S. 975, including tax, intellectual property, and liability reforms, we are confident will give us important additional tools to enlist the industry in this vital research. Let me try to briefly elaborate. BioShield II calls on this innovative spirit that I have talked about. We need to get companies and investors to commit their resources to this effort, and since intentional, maliciously infected infectious disease and naturally occurring infectious disease may have equally devastating effects, the incentives that we are proposing are extended to countermeasures to nature's threats as well. And I include by example pandemic flu, SARS, malaria, and ebola virus. Just as we in the United States seek to protect ourselves from new infectious disease threats, clearly, less developed nations are trying to eliminate scourges that have restricted their social and economic development for too long now, and BioShield II seeks to inspire innovation on behalf of neglected markets worldwide." Statements, letters, and materials submitted for the record include those of the following: Richard Burr, Joseph I. Lieberman, Orrin G. Hatch, Charles E. Schumer, and Edward M. Kennedy.
S. Hrg. 109-210; Senate Hearing 109-210
Government Printing Office: http://www.gpoaccess.gov